Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization
Por:
Sanchez-Heras A, Castillejo A, Garcia-Diaz J, Robledo M, Teule A, Sanchez R, Zuniga A, Lastra E, Duran M, Llort G, Yague C, Cajal T, San Martin C, Lopez-Fernandez A, Balmana J, Robles L, Mesa-Latorre J, Chirivella I, Fonfria M, Ibanez R, Castillejo M, Escandell I, Gomez L, Berbel P, Soto J
Publicada:
1 nov 2020
Resumen:
Simple Summary
Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome is a very rare hereditary disorder characterized by cutaneous leiomyomas (CLMs), uterine leiomyomas (ULMs), renal cysts (RCys) and renal cell cancer (RCC), with no data on its prevalence worldwide. No genotype-phenotype associations have been described. The aim of our study was to describe the genotypic and phenotypic features of the largest series of patients with HLRCC from Spain reported to date. Of 27 FH germline pathogenic variants, 12 were not previously reported in databases. Patients with missense pathogenic variants showed higher frequencies of CLMs, ULMs and RCys, than those with loss-of-function variants. The frequency of RCCs (10.9%) was lower than those reported in the previously published series.
Hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC) is a very rare hereditary disorder characterized by cutaneous leiomyomas (CLMs), uterine leiomyomas (ULMs), renal cysts (RCys) and renal cell cancers (RCCs). We aimed to describe the genetics, clinical features and potential genotype-phenotype associations in the largest cohort of fumarate hydratase enzyme mutation carriers known from Spain using a multicentre, retrospective study of individuals with a genetic or clinical diagnosis of HLRCC. We collected clinical information from medical records, analysed genetic variants and looked for genotype-phenotype associations. Analyses were performed using R 3.6.0. software. We included 197 individuals: 74 index cases and 123 relatives. CLMs were diagnosed in 65% of patients, ULMs in 90% of women, RCys in 37% and RCC in 10.9%. Twenty-seven different pathogenic variants were detected, 12 (44%) of them not reported previously. Patients with missense pathogenic variants showed higher frequencies of CLMs, ULMs and RCys, than those with loss-of-function variants (p = 0.0380, p = 0.0015 and p = 0.024, respectively). This is the first report of patients with HLRCC from Spain. The frequency of RCCs was lower than those reported in the previously published series. Individuals with missense pathogenic variants had higher frequencies of CLMs, ULMs and RCys.
Filiaciones:
Sanchez-Heras A:
Hosp Gen Univ Elche, Med Oncol Dept, Canc Genet Counselling Unit, Elche 03203, Spain
Castillejo A:
Hosp Gen Univ Elche, Mol Genet Unit, Elche 03203, Spain
Garcia-Diaz J:
Univ Hosp Principe Asturias, Dept Internal Med, Clin Genet Unit, Alcala De Henares 28805, Spain
Robledo M:
Spanish Natl Canc Res Ctr CNIO, Hereditary Endocrine Canc Grp, Madrid 28029, Spain
CIBERER, Madrid 28029, Spain
Teule A:
Inst Invest Biomed Bellvitge, Catalan Inst Oncol, Hereditary Canc Program, Lhospitalet De Llobregat 08908, Spain
Sanchez R:
Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Unidad Multidisciplinar Enfermedades Baja Prevale, Alicante 03015, Spain
Zuniga A:
Hosp Univ Politecn La Fe, Unit Genet, Valencia 46026, Spain
Lastra E:
Hosp Univ Burgos, Unidad Consejo Genet Canc Hereditario, Serv Oncol Med, Burgos 09006, Spain
Duran M:
UVA, CSIC, Inst Biol & Genet Mol IBGM, Genet Canc, Valladolid 47003, Spain
Llort G:
Corp Sanitaria Univ Parc Tauli, Med Oncol Dept, Hereditary Canc Unit, Sabadell 08208, Spain
Yague C:
Consorci Sanitari Terrassa, Med Oncol Dept, Hereditary Canc Unit, Rubi 08191, Spain
Cajal T:
Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona 08091, Spain
San Martin C:
Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona 08091, Spain
Lopez-Fernandez A:
Hosp Univ Vall dHebron, Med Oncol Dept VHIO, Hereditary Canc Genet Grp, Barcelona 08035, Spain
Balmana J:
Hosp Univ Vall dHebron, Med Oncol Dept VHIO, Hereditary Canc Genet Grp, Barcelona 08035, Spain
Robles L:
Hosp Univ 12 Octubre, Unidad Canc Familiar, Serv Oncol Med, Madrid 28041, Spain
Mesa-Latorre J:
Univ Hosp Principe Asturias, Dept Internal Med, Clin Genet Unit, Alcala De Henares 28805, Spain
Chirivella I:
Univ Valencia, INCLIVA Biomed Res Inst, Dept Med Oncol, Valencia 46010, Spain
Fonfria M:
Consorcio Hosp Prov Castellon, Med Oncol Dept, Canc Genet Counselling Unit, Castellon de La Plana 12002, Spain
Ibanez R:
Hosp Gen Univ Elche, Med Oncol Dept, Canc Genet Counselling Unit, Elche 03203, Spain
Castillejo M:
Hosp Gen Univ Elche, Mol Genet Unit, Elche 03203, Spain
Escandell I:
Hosp Gen Univ Elda, Serv Dermatol, Elda 03600, Spain
Gomez L:
Hosp Univ St Joan de Alicante, Urol Dept, St Joan De Alicante 03550, Spain
Berbel P:
Univ Miguel Hernandez, Fac Med, Dept Histol & Anat, St Joan De Alicante 03550, Spain
Soto J:
Hosp Gen Univ Elche, Mol Genet Unit, Elche 03203, Spain
|